Holocene Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Holocene Advisors’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-37,911	Closed	-$1.05M	–	951
2022 Q3	$1.05M	Hold	37,911	–	–	0.01%	610
2022 Q2	$1M	Hold	37,911	–	–	0.01%	661
2022 Q1	$3.03M	Hold	37,911	–	–	0.02%	390
2021 Q4	$7.73M	Hold	37,911	–	–	0.04%	252
2021 Q3	$12.3M	Hold	37,911	–	–	0.07%	228
2021 Q2	$9.85M	Buy	37,911 +8,134	+27%	+$2.48M	0.06%	232
2021 Q1	$11.5M	Buy	29,777 +11,315	+61%	+$4.56M	0.07%	207
2020 Q4	$7.72M	Buy	+18,462	New	+$5.82M	0.05%	257

Other funds holding VINC

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Holocene Advisors's VINC Position: Q4 2022 in Review

Holocene Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2022, closing a stake of 37,911 shares — an estimated $1.05M sold.

Holocene Advisors first reported a position in VINC in Q4 2020 and held it in 8 quarters. The position peaked at $12.3M in Q3 2021. 35 funds tracked by Wall St. Rank hold VINC as of Q4 2022.

Holocene Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Holocene Advisors sold 37,911 Vincerx Pharma, Inc. Common Stock shares in Q4 2022, an estimated $1.05M.
Holocene Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Holocene Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $12.3M in Q3 2021.
35 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2022.

Based on Holocene Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.